Literature DB >> 15570088

Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.

Barry D Anderson1, Peter C Adamson, Susan L Weiner, Mary S McCabe, Malcolm A Smith.   

Abstract

Federal regulations prescribe distinct protections for children participating in research studies. Procedures for collecting tissue specimens from children solely for research purposes must pose no more than a minor increase over minimum risk, thereby limiting the approvable correlative biologic studies to evaluate molecularly targeted agents in children with cancer. Ethical issues arise when approvable correlative studies are a mandatory component of an early-phase pediatric clinical trial of new anticancer agents. The National Cancer Institute Cancer Therapy Evaluation Program sponsored a workshop in 2002 to discuss tissue collection for correlative biologic studies in early-phase childhood cancer clinical studies of molecularly targeted agents. Workshop participants recommended the following: (1) tissue specimens for correlative studies should provide vital clinical and scientific results to qualify for early-phase pediatric study consideration; (2) parents should receive a realistic appraisal of the risks, requirements, and potential for benefit of phase I protocol participation; (3) investigators should clearly distinguish clinically necessary procedures from research procedures of no benefit to the child to improve correlative study informed consent; and (4) participation in correlative research studies included in clinical trials generally should be voluntary. The need to acquire important biologic data regarding new molecular agents will challenge the ingenuity of pediatric cancer researchers, necessitating the application of highly sensitive laboratory assay methods, new imaging procedures, and preclinical models of childhood cancer. Such innovative methods can allow necessary scientific information to be obtained while simultaneously respecting the protections appropriately afforded to children participating in research studies and minimizing the burden of research participation for children with cancer and their families.

Entities:  

Mesh:

Year:  2004        PMID: 15570088     DOI: 10.1200/JCO.2004.02.138

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  15 in total

1.  An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience.

Authors:  Arzu Onar; Uma Ramamurthy; Dana Wallace; James M Boyett
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

2.  Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.

Authors:  Stacey L Berg; Naomi Winick; Ashish Mark Ingle; Peter C Adamson; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

3.  Safety and diagnostic accuracy of tumor biopsies in children with cancer.

Authors:  Rodrigo B Interiano; Amos H P Loh; Nathan Hinkle; Fazal N Wahid; Alpin D Malkan; Armita Bahrami; Jesse J Jenkins; Shenghua Mao; Jianrong Wu; Kimberly Proctor; Victor M Santana; Alberto S Pappo; Robert E Gold; Andrew M Davidoff
Journal:  Cancer       Date:  2014-12-18       Impact factor: 6.860

4.  Burdensome Research Procedures in Trials: Why Less Is More.

Authors:  Jonathan Kimmelman; David B Resnik; Jeffrey Peppercorn; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

5.  Regulatory and ethical issues for phase I in utero gene transfer studies.

Authors:  Carson Strong
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

6.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Authors:  Elizabeth A Raetz; Mitchell S Cairo; Michael J Borowitz; Susan M Blaney; Mark D Krailo; Tarek A Leil; Joel M Reid; David M Goldenberg; William A Wegener; William L Carroll; Peter C Adamson
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

7.  Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling.

Authors:  Barrie Cohen; Michael Roth; Jonathan M Marron; Stacy W Gray; David S Geller; Bang Hoang; Richard Gorlick; Katherine A Janeway; Jonathan Gill
Journal:  Ann Surg Oncol       Date:  2016-07-26       Impact factor: 5.344

8.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Authors:  Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

9.  Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Authors:  Michael J Overman; Janhavi Modak; Scott Kopetz; Ravi Murthy; James C Yao; Marshall E Hicks; James L Abbruzzese; Alda L Tam
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

10.  Ethical issues in health research in children.

Authors: 
Journal:  Paediatr Child Health       Date:  2008-10       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.